Proposed review of the 2023 scheme to control the cost of branded health service medicines

Proposed review of the 2023 scheme to control the cost of branded health service medicines The government is proposing updates to the statutory scheme to make sure that the scheme can continue to meet its objectives from 2024 onwards, whether this is alongside a successor voluntary scheme or as a standalone scheme in the absence of this. The consultation sets out proposed amendments in three main areas: increasing the allowed growth rate which will have the effect of changing the payment percentages; revising which sales of branded medicines are exempt from scheme payments; and a new approach to control spending on older branded medicines. Department of Health and Social Care